[Media Releases] LegoChem's next-generation ADC technology (Money Today the Bell, 4 July 2014)

Title:  LegoChem’s next-generation ADC technology

Publication: Money Today the Bell / Dong-Hee Kim

Date: 4 July 2014

URL: link to website (contents in Korean)

Summary

·         Antibody-drug conjugates (ADCs) represent an innovative oncology therapeutic application that combines the unique properties of monoclonal antibodies (mAbs) with the potent cell killing activity of cytotoxic small molecule drugs.

·         LegoChem’s ADC proprietary technology overcomes the limitation of the first generation ADCs, resulting in homogeneous and safe ADCs.

·         LegoChem is preparing to enter into the preclinical stage at the end of 2014 with its most advanced ADC pipeline, and is working on licensing deals with global biotech/pharmas.

·         LegoChem’s Cephalosporin antibiotics for gram-negative pathogenic bacteria shows great efficacy. The antibiotic therapy of this class are still scarce but are in need considering the growing number of patients with gram-negative infections.

·         LegoChem’s Oxazolidinone antibiotics demonstrated efficacy non-inferior or superior to linezolid (Zyvox) and superior safety parameters, especially with respect to myelosuppression.

·         LegoChem continues to execute on its business model to partner with global biotech/pharmaceuticals to address and solve the most important unmet medical needs of our time. 

About LegoChem Biosciences

LegoChem Biosciences, Inc. (LCB) is a research-based biotechnology company dedicated to discovering, developing, and commercializing innovative medicines by leveraging our chemistry expertise to make conventional biologics targeted and more potent for the benefit of patients with diseases of high unmet medical needs. We are advancing sustainable pipelines in therapeutic areas in antibiotics, anti-coagulants, oncology, antibody-drug conjugate (ADC), and protein-drug conjugate (PDC).